Pembrolizumab for the treatment of Hodgkin Lymphoma

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69:7–34.
   PubMed Web of Science ®Google Scholar
• WHO. Classification of tumours of haematopoietic and lymphoid tissues. Lyon: International Agency for Research on Cancer (IARC); 2017. revised 4th edition, Swerdlow SH, Campo E, Harris NL, et al. (Eds).
   Google Scholar
• Mauch PM, Kalish LA, Kadin M, et al. Patterns of presentation of Hodgkin disease. Implications for etiology and pathogenesis. Cancer. 1993;71:2062.
   PubMed Web of Science ®Google Scholar
• Steidl C, Connors JM, Gascoyne RD. Molecular pathogenesis of Hodgkin’s lymphoma: increasing evidence of the importance of the microenvironment. J Clin Oncol. 2011;29:1812–1826.
   PubMed Web of Science ®Google Scholar
• Bräuninger A, Schmitz R, Bechtel D, et al. Molecular biology of Hodgkin’s and Reed/Sternberg cells in Hodgkin’s lymphoma. Int J Cancer. 2006;118:1853.
   PubMed Web of Science ®Google Scholar
• Roemer MG, Advani RH, Ligon AH, et al. PD-L1 and PD-L2 genetic alterations define classical hodgkin lymphoma and predict outcome. J Clin Oncol. 2016;34(23):2690–2697.
   PubMed Web of Science ®Google Scholar
• Shanbhag S, Ambinder RF. Hodgkin lymphoma: a review and update on recent progress. CA Cancer J Clin. 2018;68:116.
   PubMed Web of Science ®Google Scholar
• Gonzalez VJ. Role of radiation therapy in the treatment of Hodgkin lymphoma. Curr Hematol Malig Rep. 2017;12(3):244–250.
   PubMed Web of Science ®Google Scholar
• American Cancer Society. Cancer facts & figures 2019. 2019.
   Google Scholar
• Adcetris (brentuximab vedotin) [prescribing information]. Bothell, WA: Seattle Genetics; [Cited 2020 May 6]. https://seagendocs.com/Adcetris_Full_Ltr_Master.pdf
   Google Scholar
• Connors JM, Jurczak W, Straus DJ, et al. Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin’s LYMPHOMA. N Engl J Med. 2018;378:331.
   PubMed Web of Science ®Google Scholar
• Chen R, Wang F, Zhang H, et al. Brentuximab vedotin for treatment of relapsed or refractory malignant lymphoma: results of a systematic review and meta-analysis of prospective studies. Drug Des Devel Ther. 2015;9:2277.
   PubMed Web of Science ®Google Scholar
• Rashidi A, Ebadi M, Cashen AF. Allogeneic hematopoietic stem cell transplantation in Hodgkin lymphoma: a systematic review and meta-analysis. Bone Marrow Transplant. 2016;51(4):521–528.
   PubMed Web of Science ®Google Scholar
• Bristol-Myers Squibb: Opdivo (nivolumab) Highlights of prescribing information. cited 2020 May 6]. http://packageinserts.bms.com/pi/pi_opdivo.pdf
   Google Scholar
• KEYTRUDA® (pembrolizumab) for injection, for intravenous use. cited 2020 May 6]. https://www.merck.com/product/usa/pi_circulars/k/keytruda/keytruda_pi.pdf
   Google Scholar
• Decker WK, da Silva RF, Sanabria MH, et al. Cancer immunotherapy: historical perspective of a clinical revolution and emerging preclinical animal models. Front Immunol. 2017;8:829.
   PubMed Web of Science ®Google Scholar
• Dobosz P, Dzieciątkowski T. The intriguing history of cancer immunotherapy. Front Immunol. 2019;10:2965.
   PubMed Web of Science ®Google Scholar
• Shaywitz D. The startling history behind Merck’s new cancer BLOCKBUSter. Forbes. 2017 July 26. https://www.forbes.com/sites/davidshaywitz/2017/07/26/the-startling-history-behind-mercks-new-cancer-blockbuster/#1679756b948d.
   Google Scholar
• 2019 Merck Annual Report & 2020 Proxy. [cited 2020 May 18]. https://s21.q4cdn.com/488056881/files/doc_financials/2019/q4/2019-Form-10-K-Final.pdf
   Google Scholar
• Patnaik A, Kang SP, Rasco D, et al. Phase I study of pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in patients with advanced solid tumors. Clin Cancer Res. 2015 Oct 1;21(19):4286–4293.
   PubMed Web of Science ®Google Scholar
• Longoria TC, Tewari KS. Evaluation of the pharmacokinetics and metabolism of pembrolizumab in the treatment of melanoma. Expert Opin Drug Metab Toxicol. 2016;12:1247–1253.
   PubMed Web of Science ®Google Scholar
• Pharmacology Review(s) U.S. Food and Drug Administration; Silver Spring, MD. [cited 2020 May 9]. Center for Drug Evaluation and Research, Application Number: 125514Orig1s000. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/125514Orig1s000PharmR.pdf
   Google Scholar
• Elassaiss-Schaap J, Rossenu S, Lindauer A, et al. Using model-based “learn and confirm” to reveal the pharmacokinetics-pharmacodynamics relationship of pembrolizumab in the KEYNOTE-001 trial. CPT Pharmacomet Syst Pharmacol. 2017;6:21–28.
   PubMedGoogle Scholar
• Li H, Yu J, Liu C, et al. Time dependent pharmacokinetics of pembrolizumab in patients with solid tumor and its correlation with best overall response. J Pharmacokinet Pharmacodyn. 2017;44(5):403–414.
   PubMed Web of Science ®Google Scholar
• Centanni M, Moes DJA, Trocóniz IF, et al. Clinical pharmacokinetics and pharmacodynamics of immune checkpoint inhibitors. Clin Pharmacokinet. 2019;58:835–857.
   PubMed Web of Science ®Google Scholar
• Armand P, Shipp MA, Ribrag V, et al. Programmed death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure. J Clin Oncol. 2016;34:3733–3739.
   PubMed Web of Science ®Google Scholar
• Armand P, Kuruvilla J, Michot JM, et al. KEYNOTE-013 4-year follow-up of pembrolizumab in classical Hodgkin lymphoma after brentuximab vedotin failure. Blood Adv. 2020;4(12):2617–2622.
   PubMed Web of Science ®Google Scholar
• Chen R, Zinzani PL, Fanale MA, et al. Phase II study of the efficacy and safety of pembrolizumab for relapsed/refractory classic Hodgkin lymphoma. J Clin Oncol. 2017;35(19):2125–2132.
   PubMed Web of Science ®Google Scholar
• Chen R, Zinzani PL, Lee HJ, et al. Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087. Blood. 2019;134(14):1144–1153.
   PubMed Web of Science ®Google Scholar
• Zinzani PL, Lee HJ, Armand P, et al. Three-year follow-up of Keynote-087: pembrolizumab monotherapy in relapsed/refractory classic Hodgkin lymphoma. Blood. 2019;134(Supplement_1):240.
   Web of Science ®Google Scholar
• Zinzani PL, Chen R, Armand P, et al. Pembrolizumab monotherapy in patients with primary refractory classical hodgkin lymphoma who relapsed after salvage autologous stem cell transplantation and/or brentuximab vedotin therapy: KEYNOTE-087 subgroup analysis. Leuk Lymphoma. 2020;61(4):950–954.
   PubMed Web of Science ®Google Scholar
• von Tresckow B, Fanale M, Ardeshna KM, et al. Patient-reported outcomes in KEYNOTE-087, a phase 2 study of pembrolizumab in patients with classical Hodgkin lymphoma. Leuk Lymphoma. 2019;60(11):2705–2711.
   PubMed Web of Science ®Google Scholar
• Kuruvilla J, Ramchandren R, Santoro A, et al. KEYNOTE-204: randomized, open-label, phase III study of pembrolizumab (pembro) versus brentuximab vedotin (BV) in relapsed or refractory classic Hodgkin lymphoma (R/R cHL). J Clin Oncol. 2020;38(suppl; abstr 8005). DOI: 10.1200/JCO.2020.38.15_suppl.8005.
   Google Scholar
• Saltos AN, Tanvetyanon T, Williams CC, et al. Phase I/Ib study of pembrolizumab and vorinostat in patients with metastatic NSCLC (mNSCLC). J clin oncol. 2018;36(15_suppl):9046.
   Web of Science ®Google Scholar
• Rodriguez CP, Wu V, Voutsinas JM, et al. Phase I/II trial of pembrolizumab(P) and vorinostat(V) in recurrent metastatic head and neck squamous cell carcinomas (HN) and salivary gland cancer (SGC). J clin oncol. 2018;36(15_suppl):6025.
   Web of Science ®Google Scholar
• Herrera AF, Chen L, Popplewell LL, et al. Preliminary results from a phase i trial of pembrolizumab plus vorinostat in patients with relapsed or refractory diffuse large B-cell lymphoma, follicular lymphoma, and Hodgkin lymphoma. Blood. 2019;134(Supplement_1):759.
   Web of Science ®Google Scholar
• Armand P, Chen YB, Redd RA, et al. PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem-cell transplantation. Blood. 2019;134:22–29.
   PubMed Web of Science ®Google Scholar
• Allen P, Savas H, Andrew M. Evens, et al. Brief PEMBROLIZUMAB(PEM) monotherapy results in complete and near complete responses in the majority of untreated patients with classical hodgkin lymphoma (cHL): a multicenter phase 2 PET-adapted study of sequential PEM and AVD. Blood. 2019;134(Supplement_1):235.
   Web of Science ®Google Scholar
• National Comprehensive Cancer Network. Management of Immunotherapy-Related Toxicities (Version 1.2020). [cited 2020 May 8]. https://www.nccn.org/professionals/physician_gls/pdf/immunotherapy.pdf.
   Google Scholar
• Postow MA, Sidlow R, Hellman MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378(2):158–169.
   PubMed Web of Science ®Google Scholar
• Bair SM, Strelec LE, Feldman TA, et al. Outcomes and toxicities of programmed death-1 (PD-1) inhibitors in Hodgkin lymphoma patients in the United States: a real-world, multicenter retrospective analysis. Oncologist. 2019;24(7):955–962.
   PubMed Web of Science ®Google Scholar
• Haverkos BM, Abbott D, Hamadani M, et al. PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHD. Blood. 2017;130:221–228.
   PubMed Web of Science ®Google Scholar
• Dada R, Usman B. Allogeneic hematopoietic stem cell transplantation in r/r Hodgkin lymphoma after treatment with checkpoint inhibitors: feasibility and safety. Eur J Haematol. 2019;102(2):150–156.
   PubMed Web of Science ®Google Scholar
• Grimm SE, Fayter D, Ramaekers BLT, et al. Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma: an evidence review group perspective of a NICE single technology appraisal. Pharmacoeconomics. 2019;37(10):1195–1207.
   PubMed Web of Science ®Google Scholar
• Large S, Hettle R, Balakumaran A, et al. Cost-effectiveness of pembrolizumab versus brentuximab vedotin for patients with relapsed or refractory classical Hodgkin’s lymphoma: a United States payer perspective [published online ahead of print, 2018 Nov 13]. J Med Econ. 2019;22(1):1–10.
   Google Scholar
• Ramos CA, Grover NS, Beaven AW, et al. Anti-CD30 CAR-T cell therapy in relapsed and refractory Hodgkin lymphoma [published online ahead of print, 2020 Jul 23]. J Clin Oncol. 2020:JCO2001342. doi:10.1200/JCO.20.01342.
   PubMed Web of Science ®Google Scholar
• Carreau NA, Pail O, Armand P, et al. Checkpoint blockade treatment may sensitize Hodgkin Lymphoma to subsequent therapy. [published online ahead of print, 2020 Jul 28]. Oncologist. 2020. DOI:10.1634/theoncologist.2020-0167.
   Web of Science ®Google Scholar
• Tan S, Zhang H, Chai Y, et al. An unexpected N-terminal loop in PD-1 dominates binding by nivolumab. Nat Commun. 2017;8:14369.
   PubMed Web of Science ®Google Scholar
• Na Z, Yeo SP, Bharath SR, et al. Structural basis for blocking PD-1-mediated immune suppression by therapeutic antibody pembrolizumab. Cell Res. 2017;27(1):147‐150.
   PubMed Web of Science ®Google Scholar
• Lepir T, Zaghouani M, Roche SP, et al.Nivolumab to pembrolizumab switch induced a durable melanoma response: a case report. Medicine (Baltimore). 2019;98:e13804.
   PubMed Web of Science ®Google Scholar
• Liang X, Guan Y, Zhang B, et al. Severe immune-related pneumonitis with PD-1 inhibitor after progression on previous PD-L1 inhibitor in small cell lung cancer: a case report and review of the literature. Front Oncol. 2019;9:1437.
   Google Scholar
• Bartlett NL, Chen R, Fanale MA, et al. Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies. J Hematol Oncol. 2014;7:24.
   PubMed Web of Science ®Google Scholar
• Fukuhara N, Yamamoto G, Tsujimura H, et al. Retreatment with brentuximab vedotin in patients with relapsed/refractory classical Hodgkin lymphoma or systemic anaplastic large-cell lymphoma: a multicenter retrospective study. Leuk Lymphoma. 2020;61(1):176–180.
   PubMed Web of Science ®Google Scholar
• Falchi L, Sawas A, Deng C, et al. High rate of complete responses to immune checkpoint inhibitors in patients with relapsed or refractory Hodgkin lymphoma previously exposed to epigenetic therapy. J Hematol Oncol. 2016;9:132.
   PubMed Web of Science ®Google Scholar
• Santini FC, Rizvi H, Plodkowski AJ, et al. Safety and efficacy of re-treating with immunotherapy after immune-related adverse events in patients with NSCLC. Cancer Immunol Res. 2018;6(9):1093‐1099.
   PubMed Web of Science ®Google Scholar